Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

Sabril

Known as: Sabrilex 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2010
Review
2010
Recently, the United States Food and Drug Administration approved vigabatrin (Sabril®) for the treatment of adults with… Expand
2008
2008
Vigabatrin (Sabril) is an antiepileptic drug indicated for the treatment of partial epilepsy, which is only licensed as first… Expand
2006
2006
A 52 year old woman presented with neuropathic pain in both legs. Clinical neurological and neurophysiological examinations… Expand
2004
2004
PURPOSE A case control study was conducted to assess the effect of Sabril (Vigabatrin), Lamictal (Lamotrigine) and Neurontin… Expand
  • table 3
  • table 5
  • table 4
  • table 4
Review
2000
Review
2000
Summary: Purpose: Vigabatrin (Sabril, Hoechst Marion Roussel) is an antiepilepsy drug (AED) presently marketed in 64 countries… Expand
2000
2000
Purpose: Vigabatrin (Sabril), a drug that blocks GABA transaminase, has been used in the treatment of epilepsy since 1989. There… Expand
  • table 1
  • figure 1
  • figure 2
Highly Cited
1995
Highly Cited
1995
Summary Vigabatrin (VGB) prevents seizures by irreversible inhibition of γ‐aminobutyric acid (GABA) transaminase and a resulting… Expand
Review
1994
Review
1994
Summary: Vigabatrin (VGB, Sabril) is a new antiepileptic drug used for treatment of partial and secondarily generalized tonic… Expand
Highly Cited
1993
Highly Cited
1993
The novel antiepileptic drug vigabatrin (Sabril) acts by inhibiting degradation of the inhibitory neurotransmitter gamma… Expand
1991
1991
Ten patients, suffering from drug-resistant complex partial seizures were treated for a period of up to 3 years with vigabatrin… Expand
  • table 1
  • figure 1
  • table 2
  • figure 2
  • table 3